MannKind Corp (MNKD)

• Market cap: $1.05B
• 1 day: -3.41%
• 5 days: -9.57%
• 1 month: 18.88%
• 3 months: 20.14%
• 6 months: -40.14%
• Year to date: -39.29%
• 1 year: -20.93%
• 5 years: -13.49%
• 10 years: -33.98%
• Sector: Healthcare
• Industry: Biotechnology

About: MannKind Corp is a biopharmaceutical company focused on the development and commercialization of patient-centric therapies that address serious unmet medical needs for those living with cardiometabolic and orphan lung diseases. The Company is currently commercializing three products: Afrezza (insulin human) Inhalation Powder, an ultra rapid-acting inhaled insulin indicated to improve glycemic control in adults with diabetes; Furoscix (furosemide injection), to treat fluid buildup in patients with chronic heart failure or chronic kidney disease; and the V-Go wearable insulin delivery device, which provides continuous subcutaneous infusion of insulin in adults that require insulin.

Employees: 592